Abstract: An electronic device and method for controlling the same are provided. The electronic device includes a touch-sensitive screen and a controller. The touch-sensitive screen receives a first touch-moving path and a second touch-moving path thereon, wherein at least a part of the first touch-moving path is highlighted by the second touch-moving path. The controller recognizes and stores the highlighted part of the first touch-moving path.

Abstract: A method and a device for controlling an electronic device having a touch screen are provided. The present method includes displaying a plurality of first type sub-images on the touch screen at an original angle when the electronic device is in a first state, where the first type sub-images constitute a first operation screen of the first state. The present method also includes detecting a sliding operation performed on the touch screen and flipping at least one of the first type sub-images according to the sliding operation. The present method further includes when the sliding operation corresponds to a specific gesture, flipping all the first type sub-images to a maximum angle to display a second operation screen of a second state of the electronic device and switching the electronic device from the first state to the second state.

Abstract: Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.

Abstract: Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.